Molecular probes for pancreatic cancer

胰腺癌的分子探针

• 批准号: DP0986795
• 负责人: A/Prof Mark Coster
• 金额: $ 55.55万
• 依托单位: Griffith University
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-04-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0986795
• 关键词: Molecular; probes; pancreatic; cancer

Cancer has overtaken heart disease as the main cause of premature death in Australia. Currently one in two men and one in three women are diagnosed with cancer during their lifetime. Pancreatic cancer is the fourth leading cause of cancer death in Australia, and the current lack of effective therapies results in a 1 year survival of just over 10%, and a 5 year survival of less than 5%. This project aims to identify and produce new compounds with novel mechanisms of action that will facilitate our understanding of pancreatic carcinogenesis and provide the basis for the development of new therapeutic strategies. Australians diagnosed with pancreatic cancer in the future may directly benefit from the results of this work.

癌症已取代心脏病成为澳大利亚过早死亡的主要原因。目前，有二分之一的男性和三分之一的女性在一生中被诊断出患有癌症。胰腺癌是澳大利亚癌症死亡的第四大原因，目前缺乏有效的治疗方法，导致其 1 年生存率略高于 10%，5 年生存率低于 5%。该项目旨在鉴定和生产具有新颖作用机制的新化合物，这将有助于我们了解胰腺癌的发生，并为开发新的治疗策略提供基础。未来被诊断患有胰腺癌的澳大利亚人可能会直接受益于这项工作的结果。